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Abstract: Hyaluronic acid ﬁ  llers have become popular soft tissue ﬁ  ller augmentation agents 
over the past several years. They have helped revolutionize the ﬁ  ller market with a number of 
new products available for use for our patients. The purpose of this manuscript is to review the 
characteristics of the HA ﬁ  llers and to review each of the current products currently available 
for use in the US.
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Introduction
The last several years have seen a number of new soft tissue augmentation products 
(to be commonly called “ﬁ  llers”) emerge into the armamentarium of products used 
by physicians in the treatment of the signs of aging. These products have become 
increasing popular since the advent of the use of botulinum toxin, type A, for the treat-
ment of expression lines, mainly of the upper one third of the face. In fact, in a recent 
survey conducted by the American Society for Aesthetic Plastic Surgery (ASAPS), 
the number one non-surgical procedure being performed currently in the US is the 
injection of botulinum toxin, type A, whereas the ﬁ  fth most common procedure is 
now the injection of hyaluronic acid (HA) ﬁ  llers, the topic of this manuscript. ASAPS 
data currently rank the injection of botulinum toxin number one, laser hair removal 
number two, chemical peels number three, microdermabrasion number four, and HA 
ﬁ  llers number ﬁ  ve. The numbers also represent a 12.3% increase over the use of bovine 
and human collagen treatments over the previous year and approximately 48% of all 
dermal ﬁ  ller procedures being performed (www.surgery.org/public).
The hallmark of the aging face is loss of associated subcutaneous volume over 
time. Clinically, with this loss, one commonly ﬁ  nds the signs most clinicians see 
routinely when confronted with a patient concerned with the aging face – an increase 
in facial vasculature and pigment alterations, as well as an increase in the lines and 
wrinkles of the skin. This is associated histologically with a thinning of the epidermis 
and with dermal atrophy and loss of the elastic tissues present within the dermis and 
with actinic changes with loss of dermal collagen. The treatment for this change over 
time can be multiple, from skin care products, to energy based therapies (lasers, light 
sources, and radiofrequency devices) to ﬁ  llers and toxins. HA ﬁ  llers play an integral 
part in the correction of changes associated with aging; especially those associated in 
the lower one-half of the face, from the nasolabial folds, to the vertical lip lines of the 
lips, the marionette lines around the mouth, and in the thinning of the lip itself. They 
also can be used for volume enhancement of the cheeks.
The concept of an ideal ﬁ  ller has been debated for a number of years. Without 
question, everyone wants the ideal ﬁ  ller to be easy to inject, produce reproducible Clinical Interventions in Aging 2007:2(3) 370
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results, and have longevity (lasting between 1 and 2 years). 
Further, the ideal ﬁ  ller would be painless on injection and 
nonallergenic (no skin tests required), noncarcinogenic, 
nonteratogenic, and we would expect it not to migrate once 
injected into the skin. We would like the ideal ﬁ  ller to be 
stored at room temperature, have a long shelf-life, and be free 
from all transmittable diseases. Further, we would want this 
ideal ﬁ  ller to have few, if any local adverse events, and be 
affordable to both the patient and the physician. And ﬁ  nally, 
we want the material to last, with a debate still ongoing 
between those ﬁ  llers which are temporary and those ﬁ  llers 
which are permanent. It is beyond the scope of this document 
to pursue further the temporary versus permanent debate. We 
are closer than ever with the advent of the HA ﬁ  llers.
Zyderm® and Zyplast®
In order to understand the HA ﬁ  llers and their prominent role 
in the marketplace, we must spend a little time reviewing 
the past and some of the other ﬁ  ller products on the market. 
The ﬁ  rst synthetic group of ﬁ  llers was the bovine derived 
collagen products, namely Zyderm® and Zyplast® collagen. 
The collagen material was derived from a closed herd of 
cattle and puriﬁ  ed for human use. All of the collagen-
injectable materials contain lidocaine, to ease any associated 
pain which may be associated with the injection technique. 
Zyderm® I, ﬁ  rst approved by the FDA in 1981, is a 3.5% by 
weight bovine dermal collagen, in a suspension of phosphate-
buffered physiologic saline. Zyderm® I is recommended 
for injection into the superﬁ  cial papillary dermis and was 
approved for the treatment of superﬁ  cial lines and wrinkles 
as well as shallow acne scars. Zyderm® II, FDA approved 
in 1983, contains 6.5% by weight bovine dermal collagen 
in a similar buffered saline suspension. Most clinicians felt 
this material was best used to treat acne or traumatic scars 
on the face, although it worked well for lines and wrinkles, 
too. Its injection should be into the papillary dermis. Zyplast®, 
FDA approved in 1985, is a 3.5% by weight bovine dermal 
collagen cross-linked with glutaraldehyde, making it more 
resistant to biodegradation after injection. Zyplast® is best 
injected into the mid-deep dermis and its recommended use 
is for deep lines and folds (Narins and Bowman 2005; Eppley 
and Dadvand 2006). 
Overcorrection of the defect is necessary with both 
of the Zyderm® products because of the buffered saline 
contained within the syringes. Because of the animal nature 
of the material, it was necessary to perform intradermal skin 
testing prior to the injection procedure. From early studies, 
it became clear that double skin testing, that is, skin testing 
on each forearm 4 weeks apart, reduced the apparent risk 
of allergy or hypersensitivity to a very small percentage. 
Still, even with double skin testing, approximately 3% of 
patients treated may develop hypersensitivity to the bovine 
collagen. Other adverse events, which are reported, include 
local effects such as erythema, induration, and pruritus at 
the injection sites. More rare side-effects have included 
granuloma formation and necrosis secondary to vascular 
occlusion. It was also realized that, although the standard 
injectable materials from the early 1980s up until the end of 
the 1990s, these materials were variable in their longevity, 
with most clinicians noting an approximate 3-month duration 
with the collagen products.
CosmoDerm® and CosmoPlast®
Primarily because of the Zyderm®/Zyplast® hypersensitivity 
concerns, human-derived collagen products were developed, 
known as CosmoDerm® and CosmoPlast®. These products 
were both FDA approved in 2003 for use in facial aesthetic 
surgery with the hope of decreased potential immunogenicity 
and longer lasting clinical results. These are the only ﬁ  ller 
materials available which are derived from human collagen 
– a single cell line of human ﬁ  broblasts that has over 10 
years of use in manufacturing of human based tissues used 
in a variety of medical disciplines. CosmoDerm® is used in 
a similar fashion as Zyderm® I and CosmoPlast®, similar to 
Zyplast®. Immunogenicity studies have shown a marked de-
crease in potential hypersensitivity reactions (less than 1.3%); 
however, most clinicians, hoping for longer-lasting collagen 
ﬁ  llers, are convinced that the duration of these are similar to 
the earlier collagen products, Zyderm® and Zyplast® (Mentor 
Corporation 2006).
HA ﬁ  llers
In the US, physicians were “content” using US collagen-
based products for the treatment of lines and wrinkles, folds, 
and furrows associated with the aging face throughout the 
1980s and the 1990s. In Europe, however, a revolution was 
taking shape, with products being developed that would 
soon change how the majority of US doctors would uti-
lize ﬁ  llers for our patients. This revolution began with the 
development of the HA ﬁ  llers, the topic of the remainder of 
this manuscript.
A number of HA ﬁ  llers are available in the US for use as 
ﬁ  ller materials; many more are under development process 
at the time of writing. Table 1 lists the HA ﬁ  llers that are 
available and/or are under development. In order to fully 
understand the scope of HA ﬁ  llers, and to determine which Clinical Interventions in Aging 2007:2(3) 371
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HA ﬁ  ller may be best for a particular patient, a review of 
the basic characteristics and terms are necessary. HA, or 
hyaluronan, by deﬁ  nition, is a glycosaminoglycan which 
consists of regular repeating non-sulfated disaccharide units 
of glucuronic acid and N-acetylglucosamine (Alberts et al 
2002). HA is a naturally occurring substance, a biopolymer, 
which exhibits no species and no tissue speciﬁ  city. HA is an 
essential component of the extracellular matrix of all animal 
tissues and is an abundant component of this matrix. HA is 
highly hydrophilic, that is, it attracts water, and this helps 
it form large concentrations that can occupy a large volume 
relative to its mass. It has been shown to form gels at even 
low concentrations. When water is drawn into the HA matrix, 
it has been shown to create a swelling pressure or turgor that 
enables the HA complex to withstand compressive forces. 
Thus it has been found useful as a ﬁ  ller in treating some of the 
signs of aging. The fact that HA exhibits no tissue or species 
speciﬁ  city is crucially important to minimize any untoward 
effect for potential immunologic reactions or transplantation 
rejection. The ﬁ  rst HA developed as a dermal ﬁ  ller was in 
1989 by Balazs (Balazs and Denlinger 1989), who understood 
the biocompatibility of this class of compounds and lack of 
immunogenicity. The product was not long lasting, but the 
revolution had begun.
The main differentiators for HA ﬁ  llers are: source of 
HA; concentration of HA in each syringe being utilized; the 
particulate size of the HA; whether the HA is cross-linked; the 
type of cross-linking agent used in the HA; whether the HA 
is monophasic or biphasic; and whether there is an anesthetic 
in the HA syringe. The HA source for the available ﬁ  llers are 
either avian, that found primarily in rooster combs, or from 
bacteria-sourced HA, mainly from the synthetic fermentation 
of the Staphylococcus equine bacterium. This latter source 
has become more popular recently because of potential 
allergy to the avian source owing to a high avian protein 
content, and because the bacterial-derived HA products are 
more pure, more viscous, and not derived from an animal 
source. The concentration of HA ﬁ  llers is also important. 
Those HA ﬁ  llers with higher HA concentrations displace 
more tissue and are felt to equate to longer duration of effect. 
Those HA ﬁ  llers with concentrations of 20 mg/g or more of 
HA are now considered ideal. All HA ﬁ  llers utilize a single 
ether cross-link bond to stabilize the product. The newer 
non-particulate HA ﬁ  llers are either double cross-linked, 
multi crossed-linked, or monophasic gels. They are cross-
linked with a single ether bond and have their long chains 
of HA bound to 1,4-butandiol diglycidylether (BDDA) as 
well as having the shorter HA chains bound to the network, 
also with BDDA. The resulting homogeneous mass becomes 
potentially less resistant to degradation, making for a longer-
lasting HA ﬁ  ller. As a result of these processes, and because 
these newer gels are non-particulate in formation, they 
require a higher HA concentration for the duration of effect. 
The cross-linking of HA is required to prevent biodegradation 
from free radicals and enzymes and to increase the HA ﬁ  ller 
duration. BDDA, as already mentioned, has been utilized 
with much success. A newer agent, 1, 2, 7, 8-diepoxyoctane, 
may further enhance duration. Larger HA particles tend to 
last longer and are usually used for deeper dermal injections 
and defects. Monophasic HA ﬁ  llers are cohesive gels rather 
than just HA particles. Biphasic HA ﬁ  llers are made into 
particle form. Each form has proponents – monophasic HA 
ﬁ  llers may last longer and may not migrate after injection; 
biphasic HA ﬁ  llers can be customized to particle size per 
indication and anatomic area being treated (Medical Insight 
Inc 2006).
Hylaform®
Hylaform® was the ﬁ  rst of the HA ﬁ  llers available for use 
in the US. It was developed by Genzyme Biosurgery (New 
Jersey, US) and was distributed by Inamed® (Santa Barbara, 
CA, US) before Inamed’s acquisition by Allergan, Inc. 
(Irvine, CA, US) in 2006. Hylaform® was FDA approved 
in April, 2004. Hylaform® is a sterile, colorless gel implant 
material, cross-linked with divinyl sulfone, and derived 
from an avian source, that from the rooster comb. The 
degree of cross-linking is 20%. The HA concentration in 
Hylaform® is 4.5–6.0 mg/mL and the gel particle size is 500 
um. Hylaform® is indicated for the treatment of moderate 
to severe facial wrinkles and folds. It is not recommended 
for lip enhancement or augmentation. Skin testing with this 
material is not required. Its major disadvantage is longevity, 
as most would submit that Hylaform® results generally last 
3–4 months. A second Hylaform®, Hylaform® Plus, is also 
FDA approved (October 2004), for mid to deep dermal 
injection to treat moderate to severe facial wrinkles and folds. 
Table 1  Hyaluronic acid (HA) ﬁ  llers available and under clinical 
study in the US
Currently available   Under clinical study
Hylaform® Restylane® Perlane®
Hylaform® Plus  Restylane® Fine Lines
Captique™ Puragen™ Plus
Restylane® Belotero
Juvederm™ Ultra 
Juvederm™ Ultra Plus Clinical Interventions in Aging 2007:2(3) 372
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It also is derived from an avian source, again rooster combs. 
Its cross-linking agent is also divinyl sulfone, with a 20% 
degree of cross-linking. The HA concentration of Hylaform® 
Plus is also 4.5–6.0 mg/mL but the particle size is increased, 
to 750 um. Unfortunately, longevity with this product too 
is in the 3- to 4-month range. Local adverse reactions with 
the product are not usually signiﬁ  cant, a beneﬁ  t for those 
requiring a “quick ﬁ  x” type of procedure (Manna et al 1999; 
Monheit 2004). A clinical example of the use of Hylaform® 
is found in Figure 1.
Captique™
The second FDA-cleared HA ﬁ  ller is known as Captique 
(Genzyme, Inamed, Allergan; now Mentor Corporation, Santa 
Barbara, CA, US). It was developed utilizing Genzyme’s 
proprietary non-animal stabilized HA technology. This 
averted the potential immunological problems associated 
with the previous avian source for the HA ﬁ  llers. It received 
FDA clearance in December, 2004. It is cross-linked with 
divinyl sulfone, is 20% cross-linked, contains 4.5–6.0 mg/mL 
HA, and a gel particle size of 500 μm. It is a clear, colorless 
gel that has its indication for ﬁ  ne lines and wrinkles of the 
face. Skin testing is not required prior to its injection. The 
duration of effect is typically felt to be anywhere from 3 to 
6 months (Matarasso et al 2006). An example of Captique™ 
is shown in Figure 2.
Restylane®
The next of the HA ﬁ  llers approved for use in the US was 
Restylane®, FDA approved for use in December, 2003. It is 
manufactured by Q-Med (Upsalla, Sweden) and is marketed 
in the US and Canada by Medicis, Inc. (Scottsdale, AZ, US). 
Restylane® is a non-animal stabilized HA, known as NASHA, 
produced from the fermentation of equine streptococci. It is 
cross-linked with BDDA, with a 1% degree of cross-linking. 
The HA concentration of Restylane® is 20 mg/mL and its gel 
particle size is 400 μm. Restylane® has a particulate size of 
100,000 gel particles per milliliter and is the only HA ﬁ  ller 
in this family approved in the US at the time of this writing. 
Its FDA approval is for mid-dermal applications such as 
deep wrinkle correction, lip augmentation, nasolabial fold 
correction, and for glabellar creases. Restylane® has also been 
used with success in the treatment of tear trough deformities. 
Other Restylane® products available in other countries and in 
clinical testing in the US include Restylane® Perlane® (8000 
gel particles/mL) for deeper injections and deeper defects, 
and Restylane® Fine Lines (200,000 gel particles/mL) for 
superﬁ  cial injections and superﬁ  cial defects (Matarasso 
et al 2006).
The use of Restylane® in clinical trials date back to 
the 1990s. In two separate European studies, by Duranti 
et al (1998), and Olenius (1998), duration of effect were 
evaluated and found to be 78% maintaining moderate to 
marked improvement at 8 months in the study by Duranti;  Figure 1 A clinical example of the use of Hylaform® for lip augmentation.
Figure 2   A clinical example of the use of Captique™ for nasolabial folds.Clinical Interventions in Aging 2007:2(3) 373
HA ﬁ  llers for the aging face
and 82% and 69% correction after 12 weeks and 26 weeks 
respectively in the study by Olenius. Both of these studies 
reported injection-related reactions, including treatment-
site erythema, hyperpigmentation at the treatment site, and 
pain from the injection itself of about 13%. Further analy-
sis and study of injectors from Europe in 1999 yielded an 
improvement in adverse events, with only 0.15% of patients 
experiencing localized cutaneous reactions (Friedman et al 
2002). Several cases of delayed implant hypersensitivity were 
reported in the European experience (0.4%–3.7%) prompting 
the manufacturers to introduce a more puriﬁ  ed product in 
1999 (Lowe et al 2001; Lupton et al 2001; Micheels 2001). 
Further evaluation from the European groups showed that 
with the new puriﬁ  ed product, adverse events were reduced to 
0.06% and hypersensitivity reactions were reduced to 0.02%. 
From this experience and low incidence of hypersensitiv-
ity reactions, no skin testing is required for the Restylane® 
available in the US.
The pivotal US clinical trial from Narins et al (2003), 
compared Restylane® in one nasolabial fold with Zyplast® 
collagen in the other fold. The study utilized 138 predomi-
nantly female and Caucasian individuals to receive treatment 
with both materials, one in each nasolabial fold. Patients 
returned at 2-week intervals for further treatment until both 
sides of the face reached optimal correction. The average 
number of treatment sessions required to achieve this op-
timal result was 1.4 for both products. The volume needed 
for correction was lower with Restylane® (mean 1.0 mL; 
range 0.3–2.8 mL) than for Zyplast® (mean 1.6 mL; range 
0.1–5.0 mL). The Wrinkle Severity Rating Scale score for 
Restylane® was superior at all time points (2, 4, and 6 months 
after baseline), and at 6 months after baseline: Restylane® was 
rated superior in 56.9% of patients compared with Zyplast®, 
in 9.5% of patients. The Global Aesthetic Improvement Scale 
rating was also superior for Restylane® at all time points, 
with 62% rating Restylane® superior at 6 months compared 
with Zyplast®, with only 8% rating Zyplast® superior to 
Restylane®.
Adverse events were recorded at each time visit during 
the clinical study. Mild or moderate injection site reactions 
occurred in a similar non-statistical fashion with both of 
the injectable projects (93.5% with Restylane® and 90.6% 
with Zyplast®). During the 6 month follow-up period, 
treatment-related adverse events were reported to be 26.4% 
for Restylane® and 39.1% for Zyplast®. Delayed-onset 
reactions were noted in 8.7% of patients – all resolved within 
2–3 months without treatment. No hypersensitivity reactions 
were reported during the clinical trial.
Restylane® has been used for the past several years by 
numerous injectors with very acceptable clinical results. 
Most would agree that Restylane® is injected easily through 
small-gauge (30 gauge) needles, with mild local injection-site 
reactions and pain during the injection process being its 
major concerns. Restylane® does last longer than Zyplast® 
collagen, with most feeling correction can be maintained 
from 6 to 12 months. Restylane® Perlane® has ﬁ  nished FDA 
clinical trials and is awaiting FDA approval at the time of 
this writing. Restylane® Fine Lines will appear in the future 
as well. Clinical examples of the use of Restylane® are seen 
in Figures 3 and 4.
Juvederm™
The last of the HA ﬁ  llers currently available is known as 
Juvederm™. It is manufactured by Lea Derm, a subsidiary of 
Corneal Group (Paris, France). It was developed in the US by 
Inamed® (Santa Barbara, CA, US) and currently is marketed 
by Allergan, Inc. (Irvine, CA, US). Two current formulations 
of Juvederm™ are available in the US – Juvederm™ Ultra and 
Juvederm™ Ultra Plus. Six different formulations of 
Juvederm™ have been developed, with differing concentra-
tions of HA in each formulation, ranging from 18 mg/g 
to 30 mg/g. The two available US products contain 24 
and 30 mg/g of HA, respectively, and are known as high 
Figure 3 A clinical example of the use of Restylane® for nasolabial folds.Clinical Interventions in Aging 2007:2(3) 374
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viscosity HA ﬁ  llers. They were FDA approved in June, 
2006 – Juvederm™ Ultra for deep wrinkles and defects, Juve-
derm™ Ultra Plus for deeper furrows, such as the nasolabial 
folds. The Juvederm™ family is produced from the bacterial 
fermentation of equine streptococci. The HA is cross-linked 
with a patented single-phase BDDE-phosphate buffered to 
6.5–7.3 pH. With a higher concentration of HA and more 
cross-linking than other HA ﬁ  llers, it is felt by some injec-
tors that perhaps the Juvederm™ family of products may 
persist longer than other HA ﬁ  llers and have a more smooth 
injection ﬂ  ow (Medical Insight Inc 2006), although clinical 
studies documenting these claims have not been performed 
in a head-to-head comparison against any of the other avail-
able HA ﬁ  llers.
The pivotal US clinical trial, by Baumann et al (2006), 
was a comparison of Juvederm™ products with Zyplast™ 
collagen in the treatment of nasolabial folds. Four hundred 
and twenty-three patients completed the clinical trial of 
a 24-week evaluation. Over three hundred of the patients 
received an additional treatment of the HA ﬁ  ller at the 
conclusion of the clinical trial which looked at long-term 
efﬁ  cacy. Results showed that both of the ﬁ  llers used showed 
signiﬁ  cant improvements at all points during the course of 
the 24-week clinical trial. The Juvederm™ products studied 
showed signiﬁ  cantly greater efﬁ  cacy than the bovine collagen 
product; the efﬁ  cacy increased with time and was greatest at 
24 weeks after the last treatment. Utilizing a 4 point scale, 
an improvement of at least 1 point was seen in more than 
80% of Juvederm™-treated patients compared with a 0.5 
improvement, on average, in the Zyplast™-treated patients. 
For those having an end of 24 week injection, long-term 
results showed that 57% had duration of effect at 8 months, 
37% at 10 months, and 18% at 12 months. 
Adverse events were similar in this pivotal trial for 
both the Juvederm™ and Zyplast™ sides that were treated. 
Mild to moderate treatment site reactions were seen in most 
patients; all resolved within 7 days. No long-term adverse 
reactions were noted. Patient preference data suggested a 
78% preference with Juvederm™ 30, 88% with Juvederm™ 
24HV, and 84% with Juvederm™ 30HV. From this clinical 
study, Juvederm™ 24HV and Juvederm™ 30HV were chosen 
for the US market. 
Most clinicians utilizing Juvederm™ will note that it does 
inject easily through the syringe and that results between 6 
and 12 months are commonly observed. Local injection site 
reactions are rare and there has been some discussion that the 
injection of Juvederm™ results in a more natural appearance 
than the other HA ﬁ  llers, although no clinical studies with 
regard to this debate have been performed. Clinical examples 
of Juvederm™ are seen in Figures 5 and 6.
Puragen™ and Puragen™ Plus
Other HA ﬁ  llers are in development in the US and should 
receive FDA clearance over the next several years. Mentor 
Corporation (Santa Barbara, CA, US) is primed to launch 
Figure 5   A clinical example of the use of Juvederm™ for nasolabial folds.
Figure 4   A clinical example of the use of Restylane® for nasolabial folds.Clinical Interventions in Aging 2007:2(3) 375
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Puragen™ Plus in the US. Puragen™ is currently available in 
Europe. Both Puragen™ and Puragen™ Plus, the ﬁ  rst HA ﬁ  ller 
with lidocaine added, are double cross-linked, which may 
prove of value in increasing the resistance to the degradation 
of the HA ﬁ  ller. They are both non-animal derived HA ﬁ  llers 
(Medical Insight Inc 2006). Puragen™ Plus contains 20 mg/g 
HA and its pivotal clinical trial was the ﬁ  rst in the US to evalu-
ate one HA ﬁ  ller, in this case Puragen™ Plus, versus Restylane® 
in the other nasolabial fold. Clinical trial results are not yet 
available but the European experience shows that this ﬁ  ller 
probably lasts from 6 to 12 months. Local adverse reactions, 
similar to those of the other HA ﬁ  llers, have been noted as 
well. The addition of lidocaine gives Puragen™ Plus its hook 
that is its differentiator and only time will tell whether it will 
be of clinical signiﬁ  cance. Clinical examples of Puragen™ are 
shown in Figures 7 and 8.
Belotero
The other HA ﬁ  ller currently being investigated is known as 
Belotero, manufactured by Merz Pharmaceuticals (Germany, 
Raleigh, NC, US). It is a non-animal, monophasic cross-linked 
gel. It utilizes 22.5 mg/mL HA in a patented matrix technology. 
It is also undergoing clinical testing in the US market.
Other HA ﬁ  llers will also be coming to the US over the 
next several years. There are numerous of these products 
available in Europe and looking for a home in the US. Most 
of the major pharmaceutical companies are looking to partner 
with these European companies and to bring their technology 
into the aesthetic US market. We, as physicians, will have 
many options for ﬁ  llers in the near future. This is good for 
physicians, as the prices for these ﬁ  llers should become more 
reasonable, and better for their patients, where optimal ﬁ  ll-
ers can be utilized for the many needs and defects for which 
they can be utilized. 
Currently, physicians have a choice of only a handful of 
HA ﬁ  llers available for use for these patients. Most of our 
patients are familiar with Restylane® and it is currently the 
treatment of choice for most patients. Skilled injectors will 
offer patients either Restylane® or one of the Juvaderm™ 
products, and it would be up to the injector to determine 
which of the HA ﬁ  llers they feel most comfortable inject-
ing. Head-to-head comparison studies are lacking at this 
time. These types of studies would give physicians a bet-
ter understanding of which HA ﬁ  ller works best for which 
patient and where each HA ﬁ  ller works better. Without these 
studies, it is physician preference and patient preference as 
to which products are used for patients.
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Figure 6   A clinical example of the use of Juvederm™ for nasolabial folds.
Figure 7   A clinical example of the use of Puragen™ for nasolabial folds.
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Figure 8   A clinical example of the use of Puragen™ for lip augmentation.Clinical Interventions in Aging 2007:2(3) 376
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